KD Logo

CRISPR Therapeutics AG [CRSP] Chief Operating Officer makes an insider sale of 3,366 shares worth 188,799.

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $188,799 were sold by Bruno Julianne on Jun 21 ’24. At $56.09 per share, Bruno Julianne sold 3,366 shares. The insider’s holdings dropped to 6,745 shares worth approximately $0.36 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Kulkarni Samarth sold 19,582 shares, netting a total of over 1,173,232 in proceeds. Following the sale of shares at $59.91 each, the insider now holds 208,122 shares.

Before that, Kulkarni Samarth had sold 20,000 shares from its account. In a trade valued at $1,449,628, the Chief Executive Officer traded CRISPR Therapeutics AG shares for $72.48 each. Upon closing the transaction, the insider’s holdings decreased to 20,000 shares, worth approximately $11.22 million.

Analysts at Wolfe Research started covering the stock with ‘”a Peer perform”‘ outlook in a report released in mid February. As of December 11, 2023, TD Cowen has decreased its “Market perform” rating to a “an Underperform” for CRSP. Earlier on October 17, 2023, Cantor Fitzgerald downgraded its rating. Their new recommendation was “a Neutral” for CRSP stock which previously was a “an Overweight”.

Analyzing CRSP Stock Performance

During the last five days, there has been a drop of approximately -4.82%. Over the course of the year, CRISPR Therapeutics AG shares have dropped approximately -13.90%. Shares of the company reached a 52-week high of $91.10 on 02/22/24 and a 52-week low of $51.02 on 05/10/24. A 50-day SMA is recorded $56.51, while a 200-day SMA reached $60.57. Nevertheless, trading volume fell to 0.68 million shares from 1.06 million shares the previous day.

Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)

According to the 24-hour chart, there is a support level at 53.11, which, if violated, would cause prices to drop to 52.33. In the upper region, resistance lies at 54.71. The next price resistance is at 55.53. RSI (Relative Strength Index) is 40.34 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.05, which suggests the price will decrease in the coming days. Percent R is at 91.02%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Most Popular